How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

Recursion Pharmaceuticals Inc has faced significant challenges in its financial performance, highlighted by a sharp decline in revenue growth, which fell to -32.98% in Q3 2025 from +30.14% in Q2 2025.

FEC (forward-error-correction) techniques correct errors at the receiver end of digital communications systems. In contrast with error-detection and retransmission ...

Abstract: We apply the innovations method to Viterbi decoding of convolutional codes. First, we calculate the covariance matrix of the innovation (i.e., the soft-decision input to the main decoder in ...

Abstract: Viterbi algorithm is a commonly used algorithm for Gaussian filtered minimum frequency shift keying (GMSK) demodulation, but there exist some problems such as large delay, high overhead, and ...

This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed.